Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumours: Advances, Combination Strategies, and Future Directions

Table of Contents

• Key Points
• Background: What Are Neuroendocrine Tumours and Why Does PRRT Matter?
• How PRRT Works
• Five Major Research Directions in PRRT
• Clinical Evidence: The NETTER Trials and Beyond
• Expanding PRRT to New Types of Tumours
• SSTR Antagonist PRRT: A New Approach
• Targeted Alpha Therapy (TAT)
• Combination Strategies: Boosting PRRT's Power
• What This Means for Patients
• Limitations and Challenges
• Recommendations and Future Outlook
• Frequently Asked Questions
• Source Information

Key Points

• PRRT delivers radiation selectively to somatostatin receptor-expressing neuroendocrine tumour cells, sparing normal tissue.
• In NETTER-1, median progression-free survival rose from 8.4 to 28.4 months in 229 patients with progressive midgut NETs.
• NETTER-2 supported first-line PRRT in Grade 2 and 3 gastroentero-pancreatic NETs, with a 14-month progression-free survival improvement.
• In NETTER-1, grade 3 or higher haematologic events occurred in fewer than 10% of patients; nephrotoxicity in fewer than 6%.
• SSTR-PET/CT assessment is essential before treatment to identify patients likely to benefit from PRRT.

Background: What Are Neuroendocrine Tumours and Why Does PRRT Matter?

Neuroendocrine tumours (NETs) are a diverse group of cancers that arise from the diffuse neuroendocrine system throughout the body. These tumours frequently overexpress somatostatin receptors (SSTRs), particularly the subtype 2 receptor (SSTR2). This receptor overexpression is the biological feature that makes PRRT possible.

For many years, treatment options for advanced NETs were limited. Doctors could offer somatostatin analogues, targeted biological agents, or cytotoxic chemotherapy. None of these approaches offered selective tumour targeting.

The development of peptide receptor radionuclide therapy (PRRT) represented a major paradigm shift. PRRT enables selective delivery of therapeutic radiation directly to tumour cells while sparing normal tissues. This precision approach has transformed the treatment landscape for patients with advanced NETs.

How PRRT Works

PRRT uses radiolabelled somatostatin analogues. The most commonly used compounds are [177Lu]Lu-DOTATATE and [90Y]Y-DOTATOC. These compounds link a radioactive isotope via a chelator called DOTA to a peptide backbone with high SSTR2 affinity.

After intravenous administration, the compound binds to SSTR2-expressing cells. The cell then internalises the compound. Once inside, the radioactive isotope deposits beta-particle energy locally. This energy causes DNA damage and triggers apoptosis (programmed cell death) in the tumour cell.

The first clinical data on [177Lu]Lu-DOTATATE efficacy came from the Rotterdam group in 2008 for gastroentero-pancreatic neuroendocrine tumours (GEP-NETs). The same group presented promising results for bronchial NETs in 2017.

Five Major Research Directions in PRRT

Since its approval, PRRT has evolved from a therapy for progressive midgut NETs into a versatile platform for multiple neuroendocrine neoplasms (NENs). Current research directions fall into five complementary strategies:

1. Extending PRRT to new clinical contexts. The NETTER-2 trial demonstrated that early, first-line application of [177Lu]Lu-DOTATATE plus long-acting somatostatin analogues significantly improved progression-free survival (PFS) by 14 months in Grade 2 and 3 GEP-NETs. Other efforts target rare or aggressive entities such as meningioma, medullary thyroid carcinoma (MTC), pheochromocytoma and paraganglioma (PPGL), and small-cell lung cancer (SCLC), where standard therapies are ineffective.
2. Improving tumour targeting and radiation delivery. The transition from SSTR agonists to antagonists has markedly increased tumour-to-background ratios and radiation dose delivery. Novel ligands such as JR-11 (OPS201) and LM3 exhibit enhanced receptor occupancy without internalisation, translating into superior dosimetry and potentially higher efficacy.
3. Introducing targeted alpha-particle emitters and new isotopes. Alpha-emitting radionuclides (e.g., 225Ac, 212Pb, 213Bi) deliver high-linear energy transfer (LET) radiation over short path lengths, producing irreparable DNA double-strand breaks. Early clinical trials of [225Ac]Ac-DOTATATE have reported durable responses even in patients refractory to beta-PRRT. New isotopes include emerging 67Cu and 161Tb programmes.
4. Designing rational combination strategies. Integrative approaches seek to potentiate PRRT efficacy through radiosensitising agents or immunomodulation. Examples include CAPTEM (capecitabine plus temozolomide) plus PRRT, PRRT with checkpoint inhibitors (e.g., nivolumab, pembrolizumab), and combinations with DNA-repair inhibitors (such as olaparib in the LuPARP trial).
5. Developing new peptide ligands for rare receptor systems. Beyond SSTRs, novel radiopharmaceuticals target receptors such as cholecystokinin-2 receptor (CCK2R), gastrin-releasing peptide receptor (GRPR), and glucagon-like peptide-1 receptor (GLP-1R). The CCK2R ligand DOTA-MGS5, pioneered in Innsbruck, shows promising preclinical and first-in-human data in MTC and SCLC.

Together, these developments are transforming PRRT from a single therapeutic concept into a dynamic and personalised platform for molecular oncology.

Clinical Evidence: The NETTER Trials and Beyond

The clinical establishment of PRRT was founded on the pivotal NETTER-1 trial and further consolidated recently by the phase III NETTER-2 study.

NETTER-1 enrolled 229 patients with progressive, well-differentiated midgut NETs. The trial demonstrated a remarkable prolongation of median PFS from 8.4 to 28.4 months with [177Lu]Lu-DOTATATE compared to high-dose octreotide LAR (60 mg). Objective response rates improved from 3% to 18%. Overall survival (OS) analysis confirmed a clinically relevant trend toward longer survival, with a median OS improvement of 11.7 months. The final NETTER-1 results were presented in 2021.

Toxicity remained modest. Grade 3 or higher haematologic events occurred in fewer than 10% of patients. Nephrotoxicity occurred in fewer than 6%. No cases of therapy-related myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) were recorded during long-term follow-up.

Despite lacking statistical significance due to the crossover design of the study, these results, together with favourable safety data, led to regulatory approval. The European Medicines Agency (EMA) approved PRRT in 2017, and the US Food and Drug Administration (FDA) approved it in 2018. Major clinical guidelines subsequently included PRRT. These guidelines included those from the European Neuroendocrine Tumour Society (ENETS). They also included guidelines from the European Society for Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN). Guidelines from the European Association of Nuclear Medicine/Society of Nuclear Medicine and Molecular Imaging (EANM/SNMMI) were included. Guidelines from the American Society of Clinical Oncology (ASCO) were also included.

The optimal patient for [177Lu]Lu-DOTATATE treatment has high SSTR expression as assessed by SSTR-positron emission tomography/computed tomography (PET/CT). This patient also has a relatively good Karnofsky performance status score and is progressive under long-acting somatostatin analogues.

NETTER-2 (NCT03972488) investigated first-line PRRT plus long-acting octreotide LAR in high Grade 2 (Ki-67 ≥ 10–20%) and Grade 3 (Ki-67 ≥ 20–55%) GEP-NETs. Preliminary data revealed a 14-month improvement in PFS compared with long-acting octreotide LAR alone. The safety profile was consistent, with grade 3 or higher haematologic events occurring in fewer than 14% of patients. These findings support moving PRRT to earlier lines of therapy and redefining it as a potential disease-modifying modality rather than purely palliative care. The study is active and not recruiting.

NETTER-3 (NCT06784752) is an ongoing phase III trial. It is designed to evaluate [177Lu]Lu-DOTATATE plus octreotide LAR versus octreotide LAR alone in newly-diagnosed SSTR-positive G1/G2 GEP-NETs with high disease burden. Primary completion is estimated for 2030. At this time, NETTER-3 remains ongoing and no mature results are published yet.

COMPETE (NCT03049189) is a multicenter phase III study comparing the efficacy and safety of [177Lu]Lu-edotreotide PRRT with everolimus in patients with inoperable, progressive, SSTR-positive GEP-NETs. Preliminary results presented at the last ENETS and ESMO congress showed a statistically significant improvement in median PFS with PRRT compared to everolimus (23.9 vs. 14.1 months; HR 0.67; 95% CI 0.48–0.95; stratified p = 0.022). [177Lu]Lu-edotreotide also achieved higher objective response rates (central ORR 21.9% vs. 4.2%; local ORR 30.5% vs. 8.4%).

COMPOSE (NCT04919226) is a phase III trial that enrolled patients with well-differentiated G2/G3 (Ki-67 15–55%), SSTR-positive GEP-NETs. The study is currently active but not recruiting. It evaluates the efficacy, safety, and patient-reported outcomes of first- or second-line [177Lu]Lu-edotreotide versus best standard of care. Results are awaited.

Several reports also focus on the efficacy of re-challenge PRRT in advanced NET patient settings. Phase 2 randomized clinical trials are now actively recruiting to verify the efficacy and safety of re-challenge PRRT (NCT05773274; NCT04954820). Recently, the final results from a multicenter 10-year survival study endorsed by the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) and the International Atomic Energy Agency (IAEA) were reported. These results showed the prognostic implication of [18F]FDG PET/CT for the prediction of PFS and OS in the re-challenge setting. This imaging approach may play a role in guiding treatment decisions in patients who benefited from the initial PRRT.

Expanding PRRT to New Types of Tumours

The robust safety profile of [177Lu]Lu-DOTATATE has encouraged its compassionate or investigational use in rare and aggressive NENs.

Meningioma: Inoperable or recurrent meningioma can be treated with radiosurgery or fractionated radiotherapy. However, once surgical and radiation possibilities have been exhausted, other systemic therapies have shown limited efficacy. Based on the high density of SSTR2 in more than approximately 90% of meningiomas, the first randomised clinical trial (NCT06326190) comparing [177Lu]Lu-DOTATATE with standard of care has recently begun recruitment. Results are eagerly awaited.

Medullary thyroid carcinoma (MTC): The limited success of kinase inhibitors and the frequent over-expression of SSTRs have stimulated PRRT approaches using somatostatin or gastrin analogues. Compassionate-use cases demonstrate symptomatic improvement and disease stabilisation.

Pheochromocytoma and paraganglioma (PPGL): SSTR-targeted PRRT has demonstrated biochemical responses and pain reduction across multiple patient cohorts. Accordingly, its use is supported by major oncological guidelines for unresectable, progressive PPGL.

Small-cell lung cancer (SCLC): A phase Ib/II study assessing the safety and efficacy of [177Lu]Lu-DOTATATE in newly diagnosed extensive-stage SCLC is currently underway (NCT05142696). The study combines PRRT with carboplatin, etoposide, and atezolizumab in induction, and with atezolizumab in maintenance. Autoradiography studies show CCK2R expression greater than 50% and SSTR2 less than 30% in SCLC. Translational experiences with [68Ga]Ga-DOTA-MGS5 and therapeutic [177Lu]Lu-DOTA-MGS5 suggest feasibility of receptor-mediated targeting in extensive-stage SCLC.

These efforts mark a gradual evolution of PRRT from tumour-specific to receptor-driven therapy applicable across neuroendocrine phenotypes.

SSTR Antagonist PRRT: A New Approach

Conventional PRRT uses SSTR agonists (DOTATATE, DOTATOC) that internalise after high-affinity ligand receptor binding. Some evidence suggests that SSTR antagonists bind to more receptor sites per cell and thereby achieve higher tumour uptake despite lacking internalisation. The wider receptor occupancy, slower dissociation, and increased residence time may translate into improved tumour-to-organ ratios.

Two leading antagonists are currently under clinical investigation:

• JR-11 (OPS201; [177Lu]Lu-satoreotide-tetraxetan): Phase I/II studies demonstrated up to 1.8-fold higher tumour uptake than DOTATATE and a 1.5- to 2.5-fold increase in tumour dose while maintaining comparable renal exposure.
• LM3 ([177Lu]Lu-DOTA-LM3): Early human data indicate favourable biodistribution and potentially higher efficacy at reduced peptide mass.

Patient-specific dosimetry shows increased tumour absorbed doses (up to 200 Gy) without a proportional rise in kidney or bone marrow dose. Renal dosimetry remains below 0.6 Gy/GBq. Transient grade 1–2 haematologic toxicity and mild nausea are the predominant adverse events.

Phase II/III comparative trials (e.g., NCT04919226, NCT05477576) are ongoing to evaluate PFS and safety endpoints. Antagonist PRRT is poised to redefine standard PRRT for high-burden or refractory disease.

Targeted Alpha Therapy (TAT)

Alpha emitters such as 225Ac, 213Bi, and 212Pb deliver extremely high linear energy transfer (LET) radiation (80–100 keV µm⁻¹) over micrometre distances. This causes irreparable DNA double-strand breaks while minimising collateral damage. These features make alpha emitters ideal for treating micro-metastatic or beta-resistant disease.

Compassionate and prospective studies provide early evidence of efficacy:

• [225Ac]Ac-DOTATATE: In a prospective initial experience, Ballal et al. treated 32 patients with advanced GEP-NETs who had progressed after [177Lu]Lu-DOTATATE therapy. The objective response rate was 62.5%. Long-term outcome results from the same group on 91 GEP-NET patients treated with [225Ac]Ac-DOTATATE and capecitabine showed a 24-month PFS probability of 67.5% and OS probability of 70.8%. Median PFS and OS were not reached. Reported toxicities were predominantly transient haematologic suppression.
• [212Pb]Pb-DOTAMTATE and [212Pb]Pb-VMT-α-NET: Ongoing phase I/II trials (NCT05153772, RayzeBio; NCT03466216, Radiomedix; NCT05636618, Perspective Therapeutics) are exploring safety, dosimetry, and efficacy. Early cohorts show partial responses at low activities.
• [213Bi]Bi-based compounds: Though limited by short half-life, pilot studies confirm feasibility and antitumour activity.

Preclinical data indicate synergy between alpha-PRRT and DNA-repair inhibitors (e.g., PARPi) or immune checkpoint blockade (anti-PD-1). Proof-of-concept clinical applications suggest enhanced efficacy without additional toxicity. Such findings justify integrated alpha-PRRT trials combining biological and immune modulation.

Key limitations include radionuclide supply, daughter isotope recoil, the ability to incorporate them chemically and stably into a suitable vector, and dosimetry standardization. Nonetheless, alpha-therapy represents the next transformative step toward curative radioligand strategies.

Combination Strategies: Boosting PRRT's Power

Combination therapies with PRRT merge radiobiological and systemic mechanisms for improved therapeutic indices. Radiosensitisation and augmented treatment efficacy arise through several mechanisms:

• Enhanced DNA damage and impaired repair (e.g., PARPi, temozolomide)
• Improved perfusion and oxygenation (anti-VEGF)
• SSTR up-regulation via certain cytotoxics
• Immune activation by neoantigen exposure

Chemoradionuclide therapy: The AGITG CONTROL NET study randomised patients with pancreatic or midgut NETs to [177Lu]Lu-DOTATATE with or without CAPTEM (capecitabine plus temozolomide). No significance was found for midgut NETs. However, in pancreatic NETs (p-NETs), the median PFS in the combination group was not reached versus 14 months for CAPTEM alone. Objective response rate was 44% versus 28%, respectively. The safety profile was acceptable with manageable haematotoxicity.

A complementary Innsbruck trial used [18F]FDG PET/CT to guide PRRT plus CAPTEM selection. This trial confirmed improved outcomes in metabolically active lesions, suggesting that [18F]FDG PET/CT may serve as a biomarker for radiosensitisation.

As reported above, [225Ac]Ac-DOTATATE and capecitabine in 91 patients showed promising results in both [177Lu]Lu-PRRT pretreated and [177Lu]Lu-PRRT-naive patients.

PRRT plus immune checkpoint inhibition: The rationale is based on the fact that PRRT-induced DNA damage promotes antigen release and PD-L1 up-regulation. This may sensitise tumours to immunotherapy. Preclinical models suggest that T-cell infiltration is enhanced and improved survival may be achieved when PRRT precedes anti-PD-1 by several days.

First clinical evidence includes:

• [177Lu]Lu-DOTATATE plus nivolumab: A phase I trial (NCT04525638) demonstrated acceptable toxicity and 30% partial responses in lung NETs.
• [177Lu]Lu-DOTATATE plus pembrolizumab: A pilot NANETS 2024 study showed an objective response rate of 34.6% and median PFS of 11.2 months, with grade 3–4 toxicities below 10% in G2 and G3 advanced NETs.
• [177Lu]Lu-DOTATATE plus avelumab: A phase I/II trial (NCT04261855) in Merkel Cell Cancer is active and recruiting.

PRRT plus PARP inhibition: The rationale is that DNA-repair inhibition amplifies PRRT-induced double-strand breaks. The LuPARP phase I trial combined [177Lu]Lu-DOTATATE with olaparib. Several trials are investigating this combination:

• PRRT plus talazoparib (NCT05053854): Phase I in G2 NETs (Ki-67 3–20%) from pancreatic or intestinal origin, with 24 patients.
• PRRT plus olaparib (NCT06607692): Phase II in children and adolescents with recurrent or relapsed solid tumours expressing SSTR, with 25 patients.
• PRRT plus olaparib (NCT05870423): Phase I in locally advanced or metastatic, well-differentiated (G1, G2 or G3) NETs that progressed following initial or salvage PRRT. This study is also for patients with no suitable systemic alternative options, with 24 patients.
• PRRT plus olaparib (NCT04086485): Phase I/II in advanced/metastatic, progressive, well-differentiated, inoperable GEP-NETs, with 56 patients.

Other combinations: Additional trials are exploring:

• Neoadjuvant PRRT plus surgery (NCT04609592): Phase I in metastatic G1-G2 (Ki-67 ≤ 20%) GEP-NETs with lymph nodes or liver metastases only, candidates for cytoreductive surgery, with 10 patients.
• PRRT plus SBRT (NCT07150546): Phase I in well-differentiated, G1-G2 GI NETs, unresectable, progressive after one or two prior lines of systemic therapy, with 15 patients.
• PRRT plus fulvestrant (NCT06663072): Phase II in advanced/metastatic, progressive, well-differentiated, G1-G2 (Ki-67 ≤ 20%) pNET, with 25 patients.
• PRRT plus sunitinib (NCT05687123): Phase I in metastatic, unresectable well- or moderately-differentiated pNETs of any grade, with 24 patients.

What This Means for Patients

PRRT has moved from a last-resort palliative treatment to a potential first-line therapy for certain NET patients. The NETTER-2 trial showed that using PRRT early in Grade 2 and 3 GEP-NETs improved progression-free survival by 14 months. This means patients may benefit from earlier intervention rather than waiting for disease progression on other treatments.

The safety profile of PRRT remains favourable. In NETTER-1, fewer than 10% of patients experienced serious haematologic side effects, and fewer than 6% experienced kidney problems. No cases of therapy-related MDS or AML were recorded during long-term follow-up. This safety record supports expanding PRRT to new patient groups.

For patients with rare NET types such as meningioma, MTC, PPGL, and SCLC, PRRT is being investigated as a new option. These patients often have limited effective treatments after standard therapies fail. The receptor-driven nature of PRRT means it may work across different tumour types as long as they express somatostatin receptors.

Combination strategies offer the potential for even better outcomes. Adding chemotherapy, immunotherapy, or DNA-repair inhibitors to PRRT may enhance tumour response without adding unacceptable toxicity. Clinical trials are actively testing these combinations in various patient populations.

Limitations and Challenges

Several challenges remain for the field of PRRT. For targeted alpha therapy, key limitations include radionuclide supply, daughter isotope recoil, the ability to incorporate them chemically and stably into a suitable vector, and dosimetry standardization.

For combination strategies, the optimal timing, sequence, and patient selection criteria are still being determined. Not all combinations have shown benefit in all patient groups. For example, the AGITG CONTROL NET study found no significant benefit for adding CAPTEM in midgut NETs, although pancreatic NETs did show improvement.

Long-term data on newer approaches such as alpha therapy and antagonist PRRT are still limited. Most studies have relatively short follow-up periods. The durability of responses and long-term safety profiles require further investigation.

Access to PRRT may be limited by the availability of nuclear medicine facilities and trained personnel. The complexity of dosimetry and treatment planning requires specialized expertise.

Recommendations and Future Outlook

Based on the evidence presented in this review, several recommendations emerge for patients and clinicians:

1. Consider PRRT earlier in the treatment course. The NETTER-2 results support using PRRT as first-line therapy in Grade 2 and 3 GEP-NETs, not just after other treatments fail.
2. Assess SSTR expression before treatment. SSTR-PET/CT imaging is essential to identify patients who are likely to benefit from PRRT.
3. Discuss clinical trial options. Many trials are actively recruiting for new indications, combination strategies, and re-challenge settings.
4. Monitor for side effects. While PRRT is generally well-tolerated, patients should be monitored for haematologic and renal toxicity.
5. Consider re-challenge PRRT. For patients who benefited from initial PRRT, re-treatment may be an option, guided by [18F]FDG PET/CT findings.

The future of PRRT lies in personalisation. New ligands targeting different receptors, alpha-emitting isotopes, and rational combination strategies will continue to expand the therapeutic arsenal for NET patients. The integration of PRRT into precision cancer medicine represents a paradigm shift in how we approach these complex tumours.

Ongoing trials such as NETTER-3, COMPOSE, and numerous combination studies will provide further evidence to guide clinical decision-making. As the field advances, PRRT is poised to become an even more important cornerstone of treatment for patients with neuroendocrine tumours.

Frequently Asked Questions

Am I eligible for peptide receptor radionuclide therapy (PRRT)?

PRRT is for advanced neuroendocrine tumours that carry somatostatin receptors. The most appropriate patient for [177Lu]Lu-DOTATATE has high SSTR expression on SSTR-PET/CT, a relatively good Karnofsky performance status score, and disease progressing on long-acting somatostatin analogues. In the NETTER-2 trial, PRRT was also used first-line in Grade 2 and 3 gastroentero-pancreatic NETs, so eligibility is widening.

What does PRRT actually do inside my body?

PRRT links a radioactive isotope through a chelator called DOTA to a peptide with high affinity for SSTR2. After intravenous administration, the compound binds to SSTR2-expressing tumour cells, which then internalise it. Inside the cell, the radioactive isotope deposits beta-particle energy locally, causing DNA damage and triggering apoptosis, or programmed cell death, in the tumour cell while sparing normal tissues.

How much longer could PRRT keep my tumour from growing?

In the NETTER-1 trial of 229 patients with progressive, well-differentiated midgut NETs, median progression-free survival rose from 8.4 months with high-dose octreotide LAR to 28.4 months with [177Lu]Lu-DOTATATE. Objective response rates improved from 3% to 18%. Median overall survival improved by 11.7 months, a clinically relevant trend. These are group averages, not individual predictions.

What side effects and long-term risks should I expect from PRRT?

In NETTER-1, grade 3 or higher haematologic events occurred in fewer than 10% of patients and nephrotoxicity in fewer than 6%. No cases of therapy-related myelodysplastic syndrome or acute myeloid leukemia were recorded during long-term follow-up. In NETTER-2, grade 3 or higher haematologic events occurred in fewer than 14% of patients. Monitoring for haematologic and renal toxicity is still recommended.

Can PRRT be used before other treatments, not just as a last resort?

Yes. The NETTER-2 trial supported using PRRT as first-line therapy in Grade 2 and 3 gastroentero-pancreatic NETs, showing a 14-month improvement in progression-free survival compared with long-acting octreotide LAR alone. This supports moving PRRT to earlier lines of therapy and redefining it as a potential disease-modifying modality rather than purely palliative care. NETTER-3 is testing this further.

What is targeted alpha therapy and who might it help?

Targeted alpha therapy uses alpha-emitting radionuclides such as 225Ac, 212Pb and 213Bi, which deliver high-linear energy transfer radiation over short distances, causing irreparable DNA double-strand breaks. In a prospective initial experience, 32 patients with advanced gastroentero-pancreatic NETs who had progressed after [177Lu]Lu-DOTATATE had an objective response rate of 62.5%. Long-term data are still limited, and radionuclide supply is a challenge.

What happens after PRRT, and can it be given again?

Several reports focus on re-challenge PRRT in advanced NET settings, and phase 2 randomised trials are actively recruiting to verify its efficacy and safety. A 10-year survival study endorsed by WARMTH and the IAEA showed that [18F]FDG PET/CT may help predict progression-free and overall survival in the re-challenge setting, and may guide treatment decisions in patients who benefited from initial PRRT.

When should a patient with a newly diagnosed neuroendocrine tumour seek a second opinion?

A second opinion is worth considering when PRRT is being discussed, because the evidence for when to use it is changing. The NETTER-2 trial supports first-line PRRT plus long-acting somatostatin analogues in Grade 2 and 3 gastroentero-pancreatic NETs, improving progression-free survival by 14 months, rather than waiting for progression on other treatments. SSTR-PET/CT is essential to confirm receptor expression before treatment. Many trials are recruiting for new indications, combinations, and re-challenge settings. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions.

Authors: Irene J. Virgolini, Gianpaolo Di Santo, Giulia Santo

Affiliation: Department of Nuclear Medicine, Medical University of Innsbruck, Anichstraße 35, Innsbruck 6020, Austria

Journal: European Journal of Nuclear Medicine and Molecular Imaging (2026) 53:4335–4347

DOI: https://doi.org/10.1007/s00259-025-07750-w

Publication details: Received: 21 November 2025 / Accepted: 24 December 2025 / Published online: 14 February 2026

Article type: Review Article

This patient-friendly article is based on peer-reviewed research.